A
recent research report published by P&S Intelligence on the protein expression market predicts that the market will have a healthy growth
for the next few years. According to the report, the size of the protein expression
market is projected to reach $3.0 billion by 2023. Increasing prevalence of
chronic diseases, aging population, increase in growth in life science sector,
availability of funding for protein-based research and technological
advancements are key drivers for the growth of market.
Recombinant production of proteins is one of the most powerful molecular biology techniques used in the life sciences sector for its industrial application in producing biopharmaceuticals. The ability of producing abundant volume of purified and desired recombinant protein leads to its extensive potential application such as, in industrial processes, or its use to diagnose or treat diseases. Increase in research to understand efficient expression of novel and difficult proteins through protein and cell line engineering is an essential step to support future drug discoveries. A major prerequisite for drug discovery is that recombinant proteins can be produced in adequate amount and are of appropriate quality. Major players are focusing on expanding their research activities and investing on recombinant based protein expression for production of large volume of recombinant protein to be used as biotherapeutics and are also to support drug discoveries.
Geographically, the Asia-Pacific protein expression market has been experiencing growth due increasing prevalence of diseases such as anaphylaxis and diabetes, increasing aging population, increased R&D spending, and increasing per capita income. According to International Diabetes Federation, China, India, Brazil, Bangladesh and Indonesia are the top five countries with high number of diabetic patients and have emerged as a potential market for protein expression.
The global protein expression market is highly consolidated as the top three companies constitute for two-thirds of the overall market share in 2016. ThermoFisher Scientific Inc., Merck KGaA and Agilent Technologies led the global market in 2016. ThermoFisher Scientific Inc. held almost one-third of the global protein expression market share in 2016, primarily due to the availability of protein expression products as prokaryotic, mammalian, insect cell, yeast, cell free and algae-based systems. Merck KGaA was the second largest player in global protein expression market in 2016. There is stiff competition among Promega Corporation, New England Biolabs Inc. and Takara Bio. Inc. in the global market as only these companies market cell-free based protein expression systems.
Other major players in the market are Qiagen N.V., Lonza Group Ltd., Genscript Biotech Corporation, New England Biolabs Inc. and Bio-Rad Laboratories, Inc.
Recombinant production of proteins is one of the most powerful molecular biology techniques used in the life sciences sector for its industrial application in producing biopharmaceuticals. The ability of producing abundant volume of purified and desired recombinant protein leads to its extensive potential application such as, in industrial processes, or its use to diagnose or treat diseases. Increase in research to understand efficient expression of novel and difficult proteins through protein and cell line engineering is an essential step to support future drug discoveries. A major prerequisite for drug discovery is that recombinant proteins can be produced in adequate amount and are of appropriate quality. Major players are focusing on expanding their research activities and investing on recombinant based protein expression for production of large volume of recombinant protein to be used as biotherapeutics and are also to support drug discoveries.
Geographically, the Asia-Pacific protein expression market has been experiencing growth due increasing prevalence of diseases such as anaphylaxis and diabetes, increasing aging population, increased R&D spending, and increasing per capita income. According to International Diabetes Federation, China, India, Brazil, Bangladesh and Indonesia are the top five countries with high number of diabetic patients and have emerged as a potential market for protein expression.
The global protein expression market is highly consolidated as the top three companies constitute for two-thirds of the overall market share in 2016. ThermoFisher Scientific Inc., Merck KGaA and Agilent Technologies led the global market in 2016. ThermoFisher Scientific Inc. held almost one-third of the global protein expression market share in 2016, primarily due to the availability of protein expression products as prokaryotic, mammalian, insect cell, yeast, cell free and algae-based systems. Merck KGaA was the second largest player in global protein expression market in 2016. There is stiff competition among Promega Corporation, New England Biolabs Inc. and Takara Bio. Inc. in the global market as only these companies market cell-free based protein expression systems.
Other major players in the market are Qiagen N.V., Lonza Group Ltd., Genscript Biotech Corporation, New England Biolabs Inc. and Bio-Rad Laboratories, Inc.
